Duration of treatment with etanercept and motives for discontinuation in a cohort of patients with rheumatic disease;Duración del tratamiento con etanercept y razones de discontinuación en una cohorte de pacientes con patología reumática

Reumatologia Clinica

Volumn 7, Issue 6, 2011, Pages 385-388

  Senabre Gallego, José Miguel ^a   Rosas Gómez de Salazar, José ^a   Santos Soler, Gregorio ^a   Santos Ramírez, Carlos ^b   Sánchez Barrioluengo, Mabel ^c   Salas Heredia, Esteban ^a   Barber Vallés, Xavier ^d   Cano Pérez, Catalina ^a   Llahí Vidal, Núria ^a   Riestra Juán, Rosa ^a  

^a HOSPITAL MARINA BAIXA   (Spain)

^b Hospital Marina Salud   (Spain)

^c INGENIO CSIC UPV Technical University of Valencia   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Adverse event; Artritis; Drug discontinuations; Etanercept; Survival

Indexed keywords

ETANERCEPT;

ANKYLOSING SPONDYLITIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DERMATOME; DISEASE CONTROL; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; FOLLOW UP; GASTROENTERITIS; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MELANOMA; NEOPLASM; PATIENT COMPLIANCE; PNEUMONIA; PROSPECTIVE STUDY; PROSTATE CANCER; PSORIATIC ARTHRITIS; RESPIRATORY FAILURE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SAPHO SYNDROME; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL; TREATMENT DURATION; TREATMENT WITHDRAWAL; UVEITIS;

FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MOTIVATION; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATIC DISEASES; TIME FACTORS; TREATMENT FAILURE; TREATMENT REFUSAL;

EID: 83555174394     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2011.06.005     Document Type: Article

References (22)

1. Gartlehner G., Hansen R.A., Jonas B.L., Thieda P., Lohr K.N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006, 33:2398-2408.
2. McLeod C., Bagust A., Boland A., Dagenais P., Dickson R., Dundar Y., et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007, 11:1-158. iii-iv.
3. Hetland M.L., Christensen I.J., Tarp U., Dreyer L., Hansen A., Hansen I.T., et al. Østergaard M.Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62:22-32.
4. Kristensen L.E., Saxne T., Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006, 54:600-606.
5. Strangfeld A., Hierse F., Kekow J., Von Hinueber U., Tony H.P., Dockhorn R., et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009, 68:1856-1862.
6. Kristensen L.E., Karlsson J.A., Englund M., Petersson I.F., Saxne T., Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 2010, 62:1362-1369.
7. Saad A.A., Ashcroft D.M., Watson K.D., Symmons D.P., Noyce P.R., Hyrich K.L., et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010, 49:697-705.
8. Glintborg B., Østergaard M., Dreyer L., Krogh N.S., Tarp U., Hansen M.S., et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor? therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011, 2:382-390.
9. Zink A., Askling J., Dixon W.G., Klareskog L., Silman A.J., Symmons D.P. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009, 68:1240-1246.
10. Smolen J.S., Aletaha D., Koeller M., Weisman M.H., Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874.
11. Ficha técnica de Enbrel® (Pfizer).
12. Ficha técnica de Remicade® (MSD).
13. Ficha técnica de Humira® (Abbott).
14. Mohan A.K., Cote T.R., Block J.A., Manadan A.M., Siegel J.N., Braun M.M. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004, 39:295-299.
15. Gomez-Reino J.J., Carmona L., Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761.
16. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
17. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med 2001, 345:1098-1104.
18. Marchesoni A., Zaccara E., Gorla R., Bazzani C., Sarzi-Puttini P., Atzeni F., et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009, 1173:837-846.
19. Pavelka K., Forejtová S., Stolfa J., Chroust K., Buresová L., Mann H., et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009, 27:958-963.
20. Carmona L., Gómez-Reino J.J. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006, 8:R72. BIOBADASER Group.
21. Rémy A., Avouac J., Gossec L., Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 2011, 29:96-103.
22. Heiberg M.S., Nordvag B.Y., Mikkelsen K., Rødevand E., Kaufmann C., Mowinckel P., et al. The Comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, observational, multicenter study. Arthritis Rheum 2005, 52:2506.